SCHEMBL25324046

SCHEMBL25324046

CCOc1ccc(OCC)c2sc(NN)nc12

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 10/20 0.67
▸ ALDH1A1 P00352 9/20 0.67
▸ KMT2A Q03164 8/20 0.67
▸ MEN1 O00255 7/20 0.67
▸ KDM4E B2RXH2 6/20 0.67
▸ MAPK1 P28482 3/20 0.67
▸ TDP1 Q9NUW8 3/20 0.67
▸ PKM P14618 2/20 0.67
▸ HSD17B10 Q99714 3/20 0.64
▸ GAA P10253 5/20 0.44
▸ LMNA P02545 5/20 0.44
▸ POLB P06746 2/20 0.44
▸ HPGD P15428 5/20 0.38
▸ SMN1; SMN2 Q16637 3/20 0.38
▸ TSHR P16473 2/20 0.38
▸ DUSP3 P51452 1/20 0.38
▸ HTT P42858 1/20 0.38
▸ NPSR1 Q6W5P4 1/20 0.38
▸ NPC1 O15118 1/20 0.37
▸ RAB9A P51151 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2136477 0.80 MAPT (1.00) MAPTALDH1A1KMT2AMEN1KDM4E
SCHEMBL25323852 0.80 KDM4E (0.68) MAPTALDH1A1KMT2AMEN1KDM4E
SCHEMBL25321763 0.80 MAPT (0.66) MAPTALDH1A1KMT2AMEN1KDM4E
SCHEMBL25326094 0.78 ALDH1A1 (0.49) MAPTALDH1A1KMT2AMEN1KDM4E
SCHEMBL2076821 0.65 SMN1; SMN2 (0.67) MAPTALDH1A1KMT2AMEN1KDM4E
SCHEMBL11479180 0.64 ALDH1A1 (0.50) MAPTALDH1A1KMT2AMEN1KDM4E
SCHEMBL27481391 0.62 TAS1R3 (0.44) MAPTALDH1A1KMT2AMEN1KDM4E
SCHEMBL8277525 0.62 KMT2A (0.58) MAPTALDH1A1KMT2AMEN1KDM4E
SCHEMBL5038688 0.61 ALDH1A1 (0.48) MAPTALDH1A1KMT2AMEN1KDM4E
SCHEMBL3455462 0.61 TDP1 (0.69) MAPTALDH1A1KMT2AMEN1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250177359-A1 COMPOUNDS FOR USE IN THE TREATMENT OF CANCER AND INFLAMMATORY CONDITIONS OULUN YLIOPISTO (FI) 2025-06-05 — — US disclosed
EP-4469046-A1 COMPOUNDS FOR USE IN THE TREATMENT OF CANCER AND INFLAMMATORY CONDITIONS Oulun Yliopisto (FI) 2024-12-04 — — EP disclosed
WO-2023144450-A1 COMPOUNDS FOR USE IN THE TREATMENT OF CANCER AND INFLAMMATORY CONDITIONS OULUN YLIOPISTO (FI) 2023-08-03 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250177359-A1 COMPOUNDS FOR USE IN THE TREATMENT OF CANCER AND INFLAMMATORY CONDITIONS NAMPT, NADK, NQO1 MAPT 1558/4885ALDH1A1 473/4885KMT2A 1966/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback